Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri Re-Launch Approved With MRI Requirement

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.

You may also be interested in...



Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s

Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.

Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s

Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.

Biogen Idec/Elan Submit Tysabri sBLA For Crohn’s Disease

Submission includes labeling and risk management plan to address increased risk of progressive multifocal leukoencephalopathy.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel